Delaware
|
000-50644
|
77-0492262
|
||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Exhibit No.
|
Description
|
|
Press Release of Cutera, Inc. dated as of May 2, 2011.
|
CUTERA, INC.
|
|
Date: May 2, 2011
|
/s/ KEVIN P. CONNORS
|
Kevin P. Connors
|
|
President and Chief Executive Officer
|
|
·
|
The commencement of commercial shipments of our Excel V laser system;
|
|
·
|
The recent FDA clearance of our GenesisPlus product for onychomycosis (toenail fungus). We had been unable to initiate sales and marketing activities in our domestic market for this indication prior to receiving this clearance in April;
|
|
·
|
Our confidence in the leadership of our recently hired North American sales management team and the new growth strategies we put in place. We believe both will result in stronger performance for the balance of the year; and
|
|
·
|
Strengthening our research and development leadership with the addition of Len DeBenedictis as our Chief Technology Officer, who was hired in the first quarter of 2011.”
|
March 31,
|
December 31,
|
March 31,
|
||||||||||
2011
|
2010
|
2010
|
||||||||||
Assets
|
||||||||||||
Current assets:
|
||||||||||||
Cash and cash equivalents
|
$ | 13,164 | $ | 12,519 | $ | 22,519 | ||||||
Marketable investments
|
75,934 | 77,484 | 73,733 | |||||||||
Accounts receivable, net
|
3,334 | 4,208 | 3,488 | |||||||||
Inventories, net
|
7,268 | 6,448 | 6,953 | |||||||||
Deferred tax asset
|
14 | 63 | 178 | |||||||||
Other current assets and prepaid expenses
|
1,665 | 2,740 | 3,190 | |||||||||
Total current assets
|
101,379 | 103,462 | 110,061 | |||||||||
Property and equipment, net
|
668 | 597 | 796 | |||||||||
Long-term investments
|
6,492 | 6,784 | 7,153 | |||||||||
Intangibles, net
|
589 | 637 | 781 | |||||||||
Deferred tax asset, net of current portion
|
321 | 325 | 97 | |||||||||
Total assets
|
$ | 109,449 | $ | 111,805 | $ | 118,888 | ||||||
Liabilities and Stockholders' Equity
|
||||||||||||
Current liabilities:
|
||||||||||||
Accounts payable
|
$ | 1,545 | $ | 1,296 | $ | 1,898 | ||||||
Accrued liabilities
|
5,861 | 6,194 | 7,328 | |||||||||
Deferred revenue
|
5,671 | 5,633 | 6,270 | |||||||||
Total current liabilities
|
13,077 | 13,123 | 15,496 | |||||||||
Deferred rent
|
1,478 | 1,501 | 1,398 | |||||||||
Deferred revenue, net of current portion
|
1,045 | 1,287 | 1,594 | |||||||||
Income tax liability
|
479 | 477 | 729 | |||||||||
Total liabilities
|
16,079 | 16,388 | 19,217 | |||||||||
Stockholders’ equity:
|
||||||||||||
Common stock
|
14 | 14 | 13 | |||||||||
Additional paid-in capital
|
92,051 | 90,423 | 86,150 | |||||||||
Retained earnings
|
2,881 | 6,736 | 15,236 | |||||||||
Accumulated other comprehensive loss
|
(1,576 | ) | (1,756 | ) | (1,728 | ) | ||||||
Total stockholders' equity
|
93,370 | 95,417 | 99,671 | |||||||||
Total liabilities and stockholders' equity
|
$ | 109,449 | $ | 111,805 | $ | 118,888 |
Three Months Ended
|
||||||||||||
March 31,
|
December 31,
|
March 31,
|
||||||||||
2011
|
2010
|
2010
|
||||||||||
Net revenue
|
$ | 11,621 | $ | 15,216 | $ | 13,749 | ||||||
Cost of revenue
|
5,224 | 6,233 | 5,829 | |||||||||
Gross profit
|
6,397 | 8,983 | 7,920 | |||||||||
Operating expenses:
|
||||||||||||
Sales and marketing
|
5,946 | 6,123 | 6,361 | |||||||||
Research and development
|
2,130 | 2,173 | 1,454 | |||||||||
General and administrative
|
2,328 | 2,238 | 2,242 | |||||||||
Total operating expenses
|
10,404 | 10,534 | 10,057 | |||||||||
Loss from operations
|
(4,007 | ) | (1,551 | ) | (2,137 | ) | ||||||
Interest and other income, net
|
184 | 144 | 166 | |||||||||
Loss before income taxes
|
(3,823 | ) | (1,407 | ) | (1,971 | ) | ||||||
Provision (benefit) for income taxes
|
32 | (127 | ) | 47 | ||||||||
Net loss
|
$ | (3,855 | ) | $ | (1,280 | ) | $ | (2,018 | ) | |||
Net loss per share:
|
||||||||||||
Basic and Diluted
|
$ | (0.28 | ) | $ | (0.09 | ) | $ | (0.15 | ) | |||
Weighted-average number of shares used in per share calculations:
|
||||||||||||
Basic and Diluted
|
13,667 | 13,622 | 13,438 |
Three Months Ended
|
||||||||||||
March 31,
|
December 31,
|
March 31,
|
||||||||||
2011
|
2010
|
2010
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net loss
|
$ | (3,855 | ) | $ | (1,280 | ) | $ | (2,018 | ) | |||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
Stock-based compensation
|
886 | 980 | 828 | |||||||||
Tax benefit from stock-based compensation
|
- | 8 | - | |||||||||
Excess tax deficit related to stock-based compensation
|
- | (8 | ) | - | ||||||||
Depreciation and amortization
|
157 | 157 | 194 | |||||||||
Provision for excess and obsolete inventories
|
(45 | ) | 18 | (23 | ) | |||||||
Provision for doubtful accounts receivable
|
(9 | ) | (31 | ) | (82 | ) | ||||||
Gain on sale of marketable investments, net
|
- | - | (43 | ) | ||||||||
Change in deferred tax asset
|
53 | (87 | ) | (3 | ) | |||||||
Changes in assets and liabilities:
|
||||||||||||
Accounts receivable
|
883 | (1,153 | ) | (79 | ) | |||||||
Inventories
|
(775 | ) | 678 | (522 | ) | |||||||
Other current assets and prepaid expenses
|
1,509 | 553 | 338 | |||||||||
Accounts payable
|
249 | (405 | ) | 817 | ||||||||
Accrued liabilities
|
(353 | ) | 412 | (1,760 | ) | |||||||
Deferred rent
|
(3 | ) | (42 | ) | (55 | ) | ||||||
Deferred revenue
|
(204 | ) | (139 | ) | (264 | ) | ||||||
Income tax liability
|
2 | (89 | ) | (20 | ) | |||||||
Net cash used in operating activities
|
(1,505 | ) | (428 | ) | (2,692 | ) | ||||||
Cash flows from investing activities:
|
||||||||||||
Acquisition of property and equipment
|
(180 | ) | (82 | ) | (95 | ) | ||||||
Proceeds from sales of marketable and long-term investments
|
4,241 | 4,030 | 14,990 | |||||||||
Proceeds from maturities of marketable investments
|
12,125 | 8,370 | 14,125 | |||||||||
Purchase of marketable investments
|
(14,778 | ) | (21,220 | ) | (26,712 | ) | ||||||
Net cash provided by (used in) investing activities
|
1,408 | (8,902 | ) | 2,308 | ||||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from exercise of stock options and employee stock purchase plan
|
742 | 138 | 74 | |||||||||
Excess tax benefit related to stock-based compensation
|
- | 8 | - | |||||||||
Net cash provided by financing activities
|
742 | 146 | 74 | |||||||||
Net increase/(decrease) in cash and cash equivalents
|
645 | (9,184 | ) | (310 | ) | |||||||
Cash and cash equivalents at beginning of period
|
12,519 | 21,703 | 22,829 | |||||||||
Cash and cash equivalents at end of period
|
$ | 13,164 | $ | 12,519 | $ | 22,519 |
Three Months Ended
|
||||||||||||||||||||||||
March 31,
|
% of
|
December 31,
|
% of
|
March 31,
|
% of
|
|||||||||||||||||||
2011
|
Revenue
|
2010
|
Revenue
|
2010
|
Revenue
|
|||||||||||||||||||
Revenue By Geography:
|
||||||||||||||||||||||||
United States
|
$ | 4,207 | 36 | % | $ | 5,793 | 38 | % | $ | 4,547 | 33 | % | ||||||||||||
International
|
7,414 | 64 | % | 9,423 | 62 | % | 9,202 | 67 | % | |||||||||||||||
$ | 11,621 | $ | 15,216 | $ | 13,749 | |||||||||||||||||||
Revenue By Product Category:
|
||||||||||||||||||||||||
Products
|
$ | 5,345 | 46 | % | $ | 8,920 | 58 | % | $ | 7,445 | 54 | % | ||||||||||||
Upgrades
|
821 | 7 | % | 869 | 6 | % | 1,203 | 9 | % | |||||||||||||||
Service
|
3,328 | 29 | % | 3,314 | 22 | % | 3,314 | 24 | % | |||||||||||||||
Titan hand piece refills
|
1,057 | 9 | % | 934 | 6 | % | 1,322 | 10 | % | |||||||||||||||
Dermal fillers and cosmeceuticals
|
1,070 | 9 | % | 1,179 | 8 | % | 465 | 3 | % | |||||||||||||||
$ | 11,621 | $ | 15,216 | $ | 13,749 |
Three Months Ended
|
||||||||||||||||||||||||
March 31,
|
December 31,
|
March 31,
|
||||||||||||||||||||||
2011
|
2010
|
2010
|
||||||||||||||||||||||
Pre-tax Stock-Based Compensation Expense:
|
||||||||||||||||||||||||
Cost of revenue
|
$ | 143 | $ | 158 | $ | 147 | ||||||||||||||||||
Sales and marketing
|
238 | 286 | 231 | |||||||||||||||||||||
Research and development
|
143 | 152 | 96 | |||||||||||||||||||||
General and administrative
|
362 | 384 | 354 | |||||||||||||||||||||
$ | 886 | $ | 980 | $ | 828 |